Twist Bioscience Corporation (TWST) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TWST Revenue Growth
Revenue Breakdown (FY 2025)
TWST's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
TWST Revenue Analysis (2016–2025)
As of May 8, 2026, Twist Bioscience Corporation (TWST) generated trailing twelve-month (TTM) revenue of $409.5 million, reflecting strong growth of +19.3% year-over-year. The most recent quarter (Q2 2026) recorded $110.7 million in revenue, up 6.8% sequentially.
Looking at the longer-term picture, TWST's 5-year compound annual growth rate (CAGR) stands at +33.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $376.6 million in 2025, representing a new all-time high.
Revenue diversification analysis shows TWST's business is primarily driven by Ngs Tools (55%), Synthetic Genes (30%), and Antibody Discovery (6%). With over half of revenue concentrated in Ngs Tools, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ILMN (+1.2% YoY), PACB (+3.9% YoY), and BEAM (+108.0% YoY), TWST has underperformed the peer group in terms of revenue growth. Compare TWST vs ILMN →
TWST Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TWSTCurrent | $409M | +19.3% | +33.1% | -36.2% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% | |
 PACB | $160M | +3.9% | +15.2% | -348.5% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 GH | $982M | +39.6% | +27.9% | -44.4% |
TWST Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $376.6M | +20.3% | $191.0M | 50.7% | $-136,259,000 | -36.2% |
| 2024 | $313.0M | +27.7% | $133.3M | 42.6% | $-220,831,000 | -70.6% |
| 2023 | $245.1M | +20.4% | $89.7M | 36.6% | $-217,159,000 | -88.6% |
| 2022 | $203.6M | +53.8% | $84.2M | 41.4% | $-234,776,000 | -115.3% |
| 2021 | $132.3M | +46.9% | $51.7M | 39.1% | $-152,726,000 | -115.4% |
| 2020 | $90.1M | +65.7% | $28.7M | 31.8% | $-140,079,000 | -155.5% |
| 2019 | $54.4M | +113.9% | $7.0M | 12.8% | $-108,850,000 | -200.1% |
| 2018 | $25.4M | +136.2% | $-6,762,000 | -26.6% | $-70,559,000 | -277.5% |
| 2017 | $10.8M | +374.5% | $-13,253,000 | -123.1% | $-58,482,000 | -543.2% |
| 2016 | $2.3M | - | $-7,152,000 | -315.2% | $-43,656,000 | -1924.0% |
See TWST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TWST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TWST vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTWST — Frequently Asked Questions
Quick answers to the most common questions about buying TWST stock.
Is TWST's revenue growth accelerating or slowing?
TWST revenue is accelerating at +19.3% year-over-year, exceeding the 5-year CAGR of +33.1%. TTM revenue reached $409M. Growth momentum has increased versus prior periods.
What is TWST's long-term revenue growth rate?
Twist Bioscience Corporation's 5-year revenue CAGR of +33.1% reflects the sustained expansion pattern. Current YoY growth of +19.3% is above this long-term average.
How is TWST's revenue distributed by segment?
TWST reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.